Adam Boehler, the top official implementing the Trump administration’s priority to pay for patient outcomes rather than paying for procedures, is leaving the HHS.
President Donald Trump nominated Boehler to lead the International Development Finance Corp., which Congress created in 2018 to merge the Overseas Private Investment Corp. and the U.S. Agency for International Development’s Development Credit Authority. OPIC raises private capital to help development of emerging economies, and the Development Credit Authority provides credit guarantees to help financing in developing counties.
Bloomberg Law first reported this move in advance of the July 10 official announcement.
Boehler founded several businesses, including home-based group Landmark Health, prior to joining the Department of Health and Human Services in April 2018. He was also a leader at investment groups Francisco Partners and Accretive Inc.
Boehler has been head of the Centers for Medicare & Medicaid Innovation and served as a senior adviser to Secretary Alex Azar on value-based care. Boehler has been heavily involved in creation of the administration’s top health policy initiatives.
Boehler has worked to create models to pay primary care physicians based on value, tie prices of drugs administered in a doctor’s office to the amount other countries pay, and a drive to move more people to get dialysis in their homes.
Centers for Medicare & Medicaid Services Administrator Seema Verma said in an email to agency staff that Boehler was “instrumental in developing several comprehensive models” that the agency has released.
Boehler’s “upcoming nomination is a strong testament to the incredible job he has done leading CMMI,” she said.
“Secretary Azar and HHS appreciate the leadership and experience that Mr. Boehler has brought to the department,” an HHS spokesperson said in a statement to Bloomberg Law.
“We look forward to Mr. Boehler continuing to lead in these roles during the nomination process,” the spokesperson added.
Boehler did not respond to a request for comment.
To read more from Health Law & Business News pleaseOR Request Trial
(Updates with remarks from HHS spokesman in ninth and 10th paragraphs.)